Trial · NCT07899996
A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
NCT07899996, Phase 1, Phase 2, Recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of HB0056 in Adult Participants With Moderate to Severe Asthma. Trials, record NCT07899996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
- NCT number
- NCT07899996
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Conditions
- Asthma
- Interventions
- Placebo, HB0056
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part I(Phase Ib): AEs | From baseline to week 16 | Incidence of participants with adverse events |
| Primary | Part I (Phase Ib): Tss_max | From baseline to week 16 | The time required to reach the maximum concentration of HB0056 in the bloodstream after administration at steady state. |
| Primary | Part II (Phase II): Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) | From baseline to week 12 | |
| Secondary | Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Change from baseline in Fractional exhaled nitric oxide(FeNO) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Change from baseline in forced vital capacity(FVC) at each evaluation time | Part II (Phase II): 52 weeks | |
| Secondary | Change from baseline in The Forced Expiratory Flow 25-75% (FEF 25-75%) at each evaluation time | Part II (Phase II): 52 weeks | |
| Secondary | Change from baseline in peak expiratory flow (PEF) at each evaluation time | Part I(Phase Ib): 16 weeks | |
| Secondary | Change from baseline in Asthma Control Questionnaire( ACQ-6) at each evaluation time | Part I(Phase Ib): 16 weeksPart II (Phase II): 52 weeks | |
| Secondary | Annualized rate of the severe asthma exacerbation event | Part II (Phase II): 52 weeks |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899996
GET https://conductscience.org/api/trials/v1/NCT07899996/registered